|
1
|
Herskovic A, Martz LK, al-Sarraf M, et al:
Combined chemotherapy and radiotherapy compared with radiotherapy
alone in patients with cancer of the esophagus. N Engl J Med.
326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
al-Sarraf M, Martz K and Herskovic A:
Progress report of combined chemoradiotherapy versus radiotherapy
alone in patients with esophageal cancer: an intergroup study. J
Clin Oncol. 15:277–284. 1997.PubMed/NCBI
|
|
3
|
Cooper JS, Guo MD, Herskovic A, et al:
Chemoradiotherapy of locally advanced esophageal cancer: long-term
follow-up of a prospective randomized trial (RTOG 85–01). Radiation
Therapy Oncology Group. JAMA. 281:1623–1627. 1999.PubMed/NCBI
|
|
4
|
Minsky BD, Neuberg D, Kelsen DP, et al:
Final report of intergroup trial 0122 (ECOG PE-289, RTOG 90–12):
Phase II trial of neoadjuvant chemotherapy plus concurrent
chemotherapy and high-dose radiation for squamous cell carcinoma of
the esophagus. Int J Radiat Oncol Biol Phys. 43:517–523.
1999.PubMed/NCBI
|
|
5
|
Minsky BD, Pajak TF, Ginsberg RJ, et al:
INT O123 (Radiation Therapy Oncology Group 94–05) phase III trial
of combined-modality therapy for esophageal cancer: high-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002.
|
|
6
|
Tanaka Y, Yoshida K, Osada S, Yamaguchi K
and Takahashi T: Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy
for advanced esophageal carcinoma: a phase I dose-escalation study.
Anticancer Res. 31:4589–4597. 2011.PubMed/NCBI
|
|
7
|
Matsutani T, Uchida E, Yoshida H, et al: A
case of advanced esophageal carcinoma with nephrotic syndrome
completely responding to chemotherapy of docetaxel, nedaplatin and
5-fluorouracil. Gan To Kagaku Ryoho. 38:439–441. 2011.(In
Japanese).
|
|
8
|
Guo JF, Zhang B, Wu F, et al: A phase II
trial of docetaxel plus nedaplatin and 5-fluorouracil in treating
advanced esophageal carcinoma. Chin J Cancer. 29:321–324. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tokairin Y, Kumagai Y and Yamazaki S: A
case of postoperative liver metastasis of esophageal cancer remains
in progression free after successfully resected. Gan To Kagaku
Ryoho. 36:2462–2464. 2009.(In Japanese).
|
|
10
|
Noda S, Kubo N, Tanaka H, et al: A case of
advanced esophageal cancer with para-aortic lymph node metastasis
with complete response (CR) to combination chemotherapy including
nedaplatin. Gan To Kagaku Ryoho. 36:2451–2453. 2009.(In
Japanese).
|
|
11
|
Matsutani T, Sasajima K, Maruyama H, et
al: A case of the oldest old patient with advanced esophageal
cancer responding completely to the combination chemotherapy of
docetaxel/5-fluorouracil/nedaplatin with radiation. Nihon
Shokakibyo Gakkai Zasshi. 106:1026–1030. 2009.(In Japanese).
|
|
12
|
Jin J, Xu X, Wang F, et al: Second-line
combination chemotherapy with docetaxel and nedaplatin for
Cisplatin-pretreated refractory metastatic/recurrent esophageal
squamous cell carcinoma. J Thorac Oncol. 4:1017–1021. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsutani T, Sasajima K, Kobayashi Y, et
al: A case of double advanced cancer with esophageal and
hypopharyngeal carcinoma responding completely to combination
chemotherapy of docetaxel/5-fluorouracil and nedaplatin with
radiation. Gan To Kagaku Ryoho. 36:835–838. 2009.(In Japanese).
|
|
14
|
Nakajima Y, Suzuki T, Haruki S, et al: A
pilot trial of docetaxel and nedaplatin in cisplatin-pretreated
relapsed or refractory esophageal squamous cell cancer.
Hepatogastroenterology. 55:1631–1635. 2008.PubMed/NCBI
|
|
15
|
Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi
K, Nishimura H and Tanigawa N: Evaluation of combined docetaxel and
nedaplatin chemotherapy for recurrent esophageal cancer compared
with conventional chemotherapy using cisplatin and 5-fluorouracil:
a retrospective study. Dis Esophagus. 21:496–501. 2008. View Article : Google Scholar
|
|
16
|
Yamazaki K, Hironaka S, Boku N, et al: A
retrospective study of second-line chemotherapy for unresectable or
recurrent squamous cell carcinoma of the esophagus refractory to
chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol.
13:150–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsumoto H, Hirai T, Hirabayashi Y, et
al: A feasible study of docetaxel/nedaplatin combined chemotherapy
for relapsed or refractory esophageal cancer patients as a 2nd-line
chemotherapy. Gan To Kagaku Ryoho. 34:725–728. 2007.(In
Japanese).
|
|
18
|
Taguchi T, Wakui A, Nabeya K, et al: A
phase II clinical study of cis-diammine glycolato platinum, 254-S,
for gastro-intestinal cancers. 254-S Gastrointestinal Cancer Study
Group. Gan To Kagaku Ryoho. 19:483–488. 1992.PubMed/NCBI
|
|
19
|
Osaka Y, Takagi Y, Hoshino S, et al:
Combination chemotherapy with docetaxel and nedaplatin for
recurrent esophageal cancer in an outpatient setting. Dis
Esophagus. 19:473–476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kleinberg L and Forastiere A:
Chemoradiation in the management of esophageal cancer. J Clin
Oncol. 25:4110–4117. 2007. View Article : Google Scholar : PubMed/NCBI
|
